Financial Performance - Revenue for the third quarter was RMB 525.7 million, a 16.28% increase year-over-year[3] - Net profit attributable to shareholders was RMB 30.4 million, a 17.13% decrease year-over-year[3] - Operating revenue for the period was 1,079,614,618.16 yuan, down from 1,145,105,818.00 yuan in the same period last year[17] - Operating costs for the period were 1,010,799,535.25 yuan, a decrease from 1,065,544,396.60 yuan in the previous year[17] - Net profit attributable to the parent company's shareholders was 19,635,357.61 RMB, with a minority shareholder loss of -112,859.07 RMB[18] - Basic and diluted earnings per share were both 0.19 RMB[19] Cash Flow - Operating cash flow for the first nine months was negative RMB 115.7 million, a 61.57% improvement year-over-year[8] - Investment cash flow for the first nine months was negative RMB 122.6 million, a 973.97% decrease year-over-year due to increased investment in the Yungu project and office building renovations[8] - Financing cash flow for the first nine months was RMB 183.1 million, a 47.26% decrease year-over-year due to increased repayment of bank loans and interest[8] - Cash flow from operating activities was -115,709,862.52 RMB, a significant improvement from -301,092,562.46 RMB in the previous period[21] - Cash flow from investing activities was -122,647,252.56 RMB, compared to 14,033,386.17 RMB in the previous period[21] - Cash flow from financing activities was 183,121,584.63 RMB, a decrease from 347,238,234.56 RMB in the previous period[21] - The company received 595,000,000.00 RMB from borrowings, an increase from 391,000,000.00 RMB in the previous period[21] - The company repaid 393,000,000.00 RMB in debt, significantly higher than the 20,000,000.00 RMB repaid in the previous period[21] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 3.19 billion, a 10.43% increase compared to the end of the previous year[3] - Total assets increased to 3,192,001,663.99 yuan, up from 2,890,469,587.02 yuan at the beginning of the period[15] - Total liabilities rose to 1,409,815,382.82 yuan, compared to 1,136,553,310.20 yuan at the start of the period[16] - Owner's equity grew to 1,782,186,281.17 yuan, up from 1,753,916,276.82 yuan at the beginning of the period[16] - Accounts receivable rose to 1,522,130,715.44 yuan, up from 1,371,620,009.09 yuan at the beginning of the period[14] - Inventory increased to 411,299,368.38 yuan, up from 274,909,613.70 yuan at the start of the period[14] - Short-term borrowings stood at 440,000,000.00 yuan, up from 409,545,194.19 yuan at the beginning of the period[15] - The company's cash and cash equivalents at the end of the period were 117,312,982.00 RMB, down from 193,509,870.32 RMB at the beginning of the period[21] R&D and Investments - R&D expenditure capitalized increased by 77.15% to RMB 15.1 million[6] - R&D expenses for the period were 43,785,813.40 yuan, down from 62,295,379.04 yuan in the same period last year[17] - Investment cash flow for the first nine months was negative RMB 122.6 million, a 973.97% decrease year-over-year due to increased investment in the Yungu project and office building renovations[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 9,008[9] - Tan Pingtao holds 44.23% of the shares, totaling 46,708,990 shares[9] - Sunshine Life Insurance Co., Ltd. holds 6.31% of the shares, totaling 6,661,246 shares[9] - Wuhan Kanghui Investment Management Center holds 4.56% of the shares, totaling 4,815,360 shares[9] - Hu Xiaoyan holds 2.96% of the shares, totaling 3,123,650 shares[9] - Chongqing Jinpu Medical Health Service Industry Equity Investment Fund holds 1.63% of the shares, totaling 1,718,800 shares[9] - Wuxi Guolian Innovation Investment Co., Ltd. holds 1.00% of the shares, totaling 1,056,000 shares[9] - Tan Pingtao's restricted shares will be released on July 28, 2025, totaling 46,708,990 shares[12] - Wuhan Kanghui Investment Management Center's restricted shares will be released on July 28, 2025, totaling 4,815,360 shares[13] - Wuxi Guolian Innovation Investment Co., Ltd.'s restricted shares were released on February 8, 2024, totaling 1,056,000 shares[13] Financial Expenses - Financial expenses increased to 15,620,339.91 yuan, up from 3,186,970.40 yuan in the previous year[17] - Interest expenses increased to 15,271,644.44 RMB, while interest income decreased to 1,083,515.51 RMB[18] Other Financial Metrics - Accounts receivable impairment provision increased by 161.77% to RMB 54.8 million[7] - Prepaid expenses increased by 224.59% to RMB 59.6 million due to increased prepayments for project materials[6] - Inventory increased by 49.61% to RMB 411.3 million due to the expansion of medical purification system integration and laboratory projects[6] - The company's third-quarter report was unaudited[22]
华康医疗(301235) - 2024 Q3 - 季度财报